This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Aripiprazole Lauroxil (monthly), ALKS 9070, injectable extended-release aripiprazole lauroxil, ALKS 9072
ALKS 9070 is a once-monthly, injectable, extended-release version of aripiprazole (Abilify) for the treatment of schizophrenia. ALKS 9070 is created using Alkermes novel, proprietary LinkeRx technology platform which enables the creation of injectable extended-release antipsychotics and other central nervous system therapies. LinkeRx technology uses linker-tail chemistry to create new molecules derived from known agents. The resulting new molecular entities are designed to have improved clinical utility, manufacturing and ease-of-use compared to other long-acting medications.
Alkermes is also developing a two-month formulation and a six-week formulation of aripiprazole lauroxil.
Aristada (Monthly) News
Pink Sheet European CHMP Opinions and MAA Updates
Pink Sheet European CHMP Opinions And MAA Updates
Additional information available to subscribers only: